GlassScriptPhysician profile
Mona L Sussman
NPI 1639321219
$7,646.12
in general payments reported to CMS, 2019-2025
23 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,595 · 2022: $1,544 · 2023: $1,283 · 2024: $1,779 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,506.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,345.27 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $1,045.86 | 2021-2024 | Farxiga, Lokelma, Andexxa |
| Shockwave Medical, INC | $696.63 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $557.81 | 2021-2023 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $413.71 | 2021-2025 | Camzyos |
| Boston Scientific Corporation | $412.70 | 2022-2025 | Avvigo Guidance System, Epic Vascular, Angiojet Ultra 5000a |
| Abiomed | $375.65 | 2025 | |
| Abbott Laboratories | $280.91 | 2021-2024 | Mitraclip, Dragonfly Opstar, Coroflow |
| Janssen Pharmaceuticals, INC | $262.09 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $233.05 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.83 | 2021-2025 | Jardiance |
| Cvrx, INC. | $180.00 | 2022 | |
| Kci USA, INC. | $122.19 | 2023 | Prevena |
| Philips North America LLC | $87.45 | 2021 | |
| Merck Sharp & Dohme LLC | $85.45 | 2022-2024 | Keytruda, Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.98 | 2023-2024 | |
| Chiesi USA, INC. | $67.37 | 2022-2023 | Kengreal, Cleviprex |
| Amgen INC. | $59.58 | 2021-2023 | Repatha |
| Acist Medical Systems, INC. | $35.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $28.17 | 2024 | |
| Terumo Medical Corporation | $23.39 | 2021 | |
| Biotronik INC. | $22.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Sussman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.